Goldman Sachs Group Inc Day One Biopharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

$596 Billion
Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,569,918 shares of DAWN stock, worth $9.92 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,569,918

Previous 1,569,918 -0.0%

Holding current value

$9.92 Million

Previous $12.4 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	BUY	$7.93 - $13.21 $8.7 Million - $14.5 Million	1,097,679 Added 232.44%	1,569,918 $12.4 Million
Q4 2024 Feb 11, 2025	SELL	$12.46 - $16.39 $16.2 Million - $21.3 Million	-1,302,068 Reduced 73.38%	472,239 $5.98 Million
Q3 2024 Nov 14, 2024	SELL	$12.72 - $16.03 $1.64 Million - $2.06 Million	-128,801 Reduced 6.77%	1,774,307 $24.7 Million
Q2 2024 Aug 13, 2024	SELL	$12.03 - $17.69 $2.82 Million - $4.15 Million	-234,383 Reduced 10.97%	1,903,108 $26.2 Million
Q1 2024 May 15, 2024	BUY	$13.56 - $17.46 $252,785 - $325,489	18,642 Added 0.88%	2,137,491 $35.3 Million
Q4 2023 Feb 13, 2024	BUY	$9.68 - $15.37 $4.58 Million - $7.26 Million	472,654 Added 28.71%	2,118,849 $30.9 Million
Q3 2023 May 14, 2024	SELL	$11.22 - $14.86 $5.3 Million - $7.02 Million	-472,654 Reduced 22.31%	1,646,195 $20.2 Million
Q3 2023 Nov 14, 2023	SELL	$11.22 - $14.86 $8.37 Million - $11.1 Million	-746,328 Reduced 31.19%	1,646,195 $20.2 Million
Q2 2023 May 14, 2024	BUY	$11.74 - $14.47 $1.28 Million - $1.58 Million	109,187 Added 4.78%	2,392,523 $28.6 Million
Q2 2023 Aug 14, 2023	BUY	$11.74 - $14.47 $1.28 Million - $1.58 Million	109,187 Added 4.78%	2,392,523 $28.6 Million
Q1 2023 May 14, 2024	BUY	$12.75 - $23.41 $6.57 Million - $12.1 Million	515,234 Added 29.14%	2,283,336 $30.5 Million
Q1 2023 May 11, 2023	BUY	$12.75 - $23.41 $6.57 Million - $12.1 Million	515,234 Added 29.14%	2,283,336 $30.5 Million
Q4 2022 May 14, 2024	BUY	$18.77 - $22.0 $806,359 - $945,120	42,960 Added 2.49%	1,768,102 $38 Million
Q4 2022 Feb 13, 2023	BUY	$18.77 - $22.0 $806,359 - $945,120	42,960 Added 2.49%	1,768,102 $38 Million
Q3 2022 May 14, 2024	SELL	$16.44 - $26.57 $2.78 Million - $4.5 Million	-169,395 Reduced 8.94%	1,725,142 $34.6 Million
Q3 2022 Nov 10, 2022	SELL	$16.44 - $26.57 $2.78 Million - $4.5 Million	-169,395 Reduced 8.94%	1,725,142 $34.6 Million
Q2 2022 May 14, 2024	SELL	$5.72 - $17.9 $1.28 Million - $4.02 Million	-224,312 Reduced 10.59%	1,894,537 $33.9 Million
Q2 2022 Aug 15, 2022	BUY	$5.72 - $17.9 $10.7 Million - $33.4 Million	1,863,325 Added 5969.9%	1,894,537 $33.9 Million
Q1 2022 May 16, 2022	BUY	$9.12 - $17.47 $60,793 - $116,455	6,666 Added 27.16%	31,212 $310,000
Q4 2021 Feb 14, 2022	BUY	$15.65 - $26.33 $384,144 - $646,296	24,546 New	24,546 $414,000

Others Institutions Holding DAWN

# of Institutions

196

Shares Held

76.7M

Call Options Held

138K

Put Options Held

208K

View Full List

About Day One Biopharmaceuticals, Inc.

Ticker DAWN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,461,104
Market Cap $464M
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...

More about DAWN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Day One Biopharmaceuticals, Inc. Transaction History